• Publications
  • Influence
The development of an EORTC quality of life questionnaire to assess chemotherapy-induced peripheral neuropathy: the QLQ-CIPN20.
Chemotherapy-induced peripheral neuropathy (CIPN) is a common phenomenon, often resulting in serious limitations in daily functioning and compromised quality of life. Currently available toxicityExpand
  • 281
  • 20
The chemotherapy-induced peripheral neuropathy outcome measures standardization study: from consensus to the first validity and reliability findings.
BACKGROUND Chemotherapy-induced peripheral neuropathy (CIPN) is a debilitating and dose-limiting complication of cancer treatment. Thus far, the impact of CIPN has not been studied in a systematicExpand
  • 190
  • 14
Epilepsy in low‐grade gliomas: The impact on cognitive function and quality of life
Low‐grade gliomas frequently are associated with epilepsy. The purpose of this study is to determine the impact of epilepsy and antiepileptic drug (AED) treatment on cognitive functioning andExpand
  • 312
  • 13
Neurotoxic Complications of Chemotherapy in Patients with Cancer
Neurotoxic side effects of chemotherapy occur frequently and are often a reason to limit the dose of chemotherapy. Since bone marrow toxicity, as the major limiting factor in most chemotherapeuticExpand
  • 253
  • 12
Pitfalls in grading severity of chemotherapy-induced peripheral neuropathy.
BACKGROUND Reliable reporting of chemotherapy-induced neurotoxicity is important. The objectives of the current study were to evaluate the differences in the peripheral neurotoxicity sections ofExpand
  • 178
  • 12
Grading of chemotherapy-induced peripheral neuropathy.
Peripheral neuropathy can be defined as a derangement in structure and function of peripheral motor, sensory, and autonomic neurons [1], causing peripheral neuropathic symptoms and signs. In routineExpand
  • 151
  • 11
  • PDF
Cognitive rehabilitation in patients with gliomas: a randomized, controlled trial.
PURPOSE Patients with gliomas often experience cognitive deficits, including problems with attention and memory. This randomized, controlled trial evaluated the effects of a multifaceted cognitiveExpand
  • 229
  • 10
  • PDF
The course of neurocognitive functioning in high-grade glioma patients.
We evaluated the course of neurocognitive functioning in newly diagnosed high-grade glioma patients and specifically the effect of tumor recurrence. Following baseline assessment (after surgery andExpand
  • 135
  • 7
Physician-assessed and patient-reported outcome measures in chemotherapy-induced sensory peripheral neurotoxicity: two sides of the same coin.
BACKGROUND The different perception and assessment of chemotherapy-induced peripheral neurotoxicity (CIPN) between healthcare providers and patients has not yet been fully addressed, although theseExpand
  • 96
  • 7
Symptoms and problems in the end-of-life phase of high-grade glioma patients.
Despite multimodal treatment, it is not possible to cure high-grade glioma (HGG) patients. Therefore, the aim of treatment is not only to prolong life, but also to prevent deterioration ofExpand
  • 140
  • 6
  • PDF